Taltz works by binding to IL-17A, inhibiting its interaction with the IL-17 receptor. This action reduces the release of proinflammatory cytokines and chemokines, thereby decreasing inflammation associated with autoimmune conditions .Indications

Taltz is indicated for the treatment of

• Plaque Psoriasis: Adults and children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

• Psoriatic Arthritis: Adults with active psoriatic arthritis.

• Ankylosing Spondylitis: Adults with active ankylosing spondylitis.

• Non-radiographic Axial Spondyloarthritis: Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation .

Administration & Dosing

Taltz is administered as a subcutaneous injection. The dosing schedule varies based on the condition being treated

• Plaque Psoriasis:

  • 160 mg at Week 0 (two 80 mg injections), followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks thereafter.

• Psoriatic Arthritis:

  • 160 mg at Week 0 (two 80 mg injections), followed by 80 mg every 4 weeks thereafter .

• Ankylosing Spondylitis:

  • 160 mg at Week 0 (two 80 mg injections), followed by 80 mg every 4 weeks thereafter 

• Non-radiographic Axial Spondyloarthritis:

  • 80 mg every 4 weeks

Side Effects

Common side effects of Taltz include:

• Upper respiratory infections

• Injection site reactions

• Headache

• Fatigue

• Diarrhea

• Nausea

Serious side effects may include:

• Increased risk of infections

• Allergic reactions

• Elevated blood pressure

• Changes in liver function tests

Patients should be monitored for signs of infection and other potential adverse effects during treatment .